ArticleMalaria journal2025
Tafenoquine lactation pharmacokinetics: a pilot study.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundRadical cure with an 8-aminoquinoline is required to prevent relapses from Plasmodium vivax. Single-dose treatment with tafenoquine offers significant advantages over primaquine, but the amount of tafenoquine excreted in breastmilk is unknown. As tafenoquine can cause serious haemolysis in G6PD deficient individuals, the amount of drug in breastmilk must be determined in order to advise on safe and effective treatment for lactating women.
methodsSix healthy lactating volunteers ≥ 1 year postpartum were recruited for this mother-only pilot pharmacokinetic study. Paired breastmilk and venous samples were taken on day 0, 1, 7 and 14. Breastmilk samples were collected in serial 5 ml aliquots to test foremilk and hindmilk drug concentrations.
resultsTafenoquine concentrations in milk were similar to concentrations in blood (milk/plasma ratio 1.09, range: 0.58-1.63). Concentrations were higher in hindmilk and in lower volume samples. Estimated drug passed to infants was calculated using a standard estimate of milk intake (150 ml per kg per day) and a high intake scenario (200 ml per kg per day). The maximum estimated dose that would be passed to the infant on a single day was 0.050 mg/kg in the first 24 h (range 0.032-0.062 mg/kg). Median weight-adjusted proportion of a therapeutic dose that infants would ingest (relative infant dose, RID) in total ranged from 5.07% (assuming of 150 ml milk per kg per day and 10 mg/kg therapeutic dose) to 13.52% (assuming 200 ml milk per kg per day and 5 mg/kg therapeutic dose). The drug was well tolerated by mothers. DISCUSSION: This pilot study demonstrated measurable tafenoquine in breastmilk, with very small amounts of drug passing to babies on any given day but overall estimated RIDs around the conventional 10% threshold for safety concerns. Further studies are needed to determine with greater certainty the excretion of tafenoquine in breastmilk and drug concentrations in infant blood to inform recommendations for breastfeeding women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.